Acute-graft-versus-host Disease Clinical Trial
Official title:
Department of Hematology of First Affiliated Hospital of Soochow University
With the stem cell transplanting increasing, patients which effected with gut GVHD were also increased. To evaluation the safety and efficacy of FMT for gut GVHD,patients with gut GVHD were recruited.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03557749 -
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
|
||
| Completed |
NCT05121142 -
Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
|
Phase 1 | |
| Completed |
NCT02175615 -
Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCT
|
||
| Recruiting |
NCT05078073 -
HBOT in the Treatment and Prevention of aGVHD
|
N/A | |
| Not yet recruiting |
NCT03605940 -
A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease
|
Phase 2 | |
| Completed |
NCT04014790 -
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT03805789 -
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04291261 -
Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease
|
Phase 2 | |
| Recruiting |
NCT05123040 -
Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04686929 -
Abatacept s.c. for aGVHD Prevention in Haplo-HCT
|
Phase 1/Phase 2 | |
| Completed |
NCT03763318 -
A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03764228 -
Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT03339297 -
An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
|
Phase 2 | |
| Active, not recruiting |
NCT03847844 -
UCMSCs as Front-line Approach of Treatment for Patients With aGVHD
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05149365 -
Sitagliptin for Prevention of aGVHD After Alternative Donor Transplantation
|
Phase 3 | |
| Not yet recruiting |
NCT04883918 -
ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
|
Phase 2 | |
| Terminated |
NCT01220297 -
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
|
Phase 2 | |
| Recruiting |
NCT05263999 -
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
|
Phase 3 | |
| Recruiting |
NCT05352269 -
Safety and Tolerability of FMT Capsules in Healthy Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT02392780 -
Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease
|
Phase 2 |